US-based pharmaceutical company Johnson & Johnson has reported data from a Phase I trial of its bispecific antibody, pasritamig, for metastatic castration-resistant prostate cancer (mCRPC).
The first-in-human trial enrolled 174 subjects aged 36–89 years who had undergone an average of four previous therapies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Results from the study indicated that pasritamig was well-tolerated and demonstrated potential anti-tumour activity in mCRPC patients.
The recommended Phase II doses (RP2D) of the antibody were 3.5mg, 18mg and 300mg intravenously, on day one, eight and 15, respectively.
Following this, subjects were given one dose of the therapy every six weeks.
The RP2D safety group also included subjects who were treated once every three weeks, as the toxicity profiles were very alike, while the efficacy group only involved subjects treated at the RP2D once every six weeks.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn the safety group, all subjects had received androgen receptor pathway inhibitors before, while 75.6% had undergone taxane chemotherapy and 37.8% had been treated with Lutetium 177 vipivotide tetraxetan radioligand therapy.
The RP2D efficacy group showed that 42.4% of subjects achieved a significant decrease in prostate-specific antigen levels, with a median radiographic progression-free survival of 7.9 months.
Pasritamig is designed to activate T-cells and direct them to work against cancer cells.
The data from this study were presented at the recent American Society of Clinical Oncology Annual Meeting.
Johnson & Johnson Innovative Medicine Early Clinical Development and Translational Research vice-president Jeff Infante said: “Metastatic castration-resistant prostate cancer remains one of the most difficult stages of prostate cancer to treat, particularly for patients who haven’t responded well to previous treatments.
“This investigational approach underscores our commitment to developing innovative and practice-changing medicines that are well-tolerated and can be easily administered in community practice settings.”
Johnson & Johnson recently reported new data from the Phase III ICONIC-TOTAL trial of icotrokinra, an oral peptide for treating plaque psoriasis.
